title: Association of bone microarchitecture with parathyroid hormone concentration and calcium intake in men: the STRAMBO study.
abstract: OBJECTVIE: In the elderly, vitamin D deficit, low calcium intake, and impaired bone microarchitecture are associated with higher risk of hip fracture. We assessed the association of bone microarchitecture with calcium intake and serum concentrations of 25-hydroxycholecalciferol (25OHD) and parathyroid hormone (PTH) in men.
  
  
  METHODS
  Cross-sectional analysis was performed in 1064 men aged 20-87 years not taking vitamin D or calcium supplements.
  
  
  METHODS
  Daily calcium intake was assessed using a food frequency questionnaire. Bone microarchitecture was assessed at distal radius and tibia by high-resolution peripheral quantitative computed tomography. We measured serum and urinary levels of biochemical bone turnover markers (BTMs). Statistical models were adjusted for age, weight, height, and glomerular filtration rate.
  
  
  RESULTS
  In 500 men aged <65 years, lower 25OHD levels and low calcium intake were associated with lower trabecular volumetric bone mineral density (Dtrab) at the distal tibia, due to lower trabecular number (Tb.N). Low calcium intake was associated with lower cortical thickness (Ct.Th). Higher PTH level was associated with higher BTM levels. In 563 men aged ≥65 years, the highest PTH quartile was associated with lower Ct.Th (tibia), lower Dtrab (both sites), and lower Tb.N (radius) compared with the lowest quartile. Low calcium intake was associated with lower Tb.N and more heterogenous trabecular distribution. BTM positively correlated with the PTH concentration.
  
  
  CONCLUSIONS
  In older men, elevated PTH concentration is associated with high bone turnover, poor trabecular microarchitecture (radius and tibia), and, at the distal tibia, lower Ct.Th. Low calcium intake is associated with lower Tb.N and more heterogenous trabecular distribution.
authors.affiliation: INSERM Research Unit 1033, Hôpital Edouard Herriot, Université de Lyon 1, Place d'Arsonval, 69437 Lyon, France.
authors.forename: A
authors.initials: A
authors.lastname: Chaitou
authors.forename: S
authors.initials: S
authors.lastname: Boutroy
authors.forename: N
authors.initials: N
authors.lastname: Vilayphiou
authors.forename: A
authors.initials: A
authors.lastname: Varennes
authors.forename: M
authors.initials: M
authors.lastname: Richard
authors.forename: S
authors.initials: S
authors.lastname: Blaizot
authors.forename: F
authors.initials: F
authors.lastname: Munoz
authors.forename: P D
authors.initials: PD
authors.lastname: Delmas
authors.forename: J
authors.initials: J
authors.lastname: Goudable
authors.forename: R
authors.initials: R
authors.lastname: Chapurlat
authors.forename: P
authors.initials: P
authors.lastname: Szulc
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D015519:Bone Density; D002112:Calcifediol / Q000097:blood; D002136:Calcium, Dietary / Q000008:administration & dosage*; D015331:Cohort Studies; D006620:Hip Fractures / Q000517:prevention & control; D006801:Humans; D008297:Male; D008875:Middle Aged; D015675:Osteocalcin / Q000097:blood; D010281:Parathyroid Hormone / Q000097:blood*; D011446:Prospective Studies; D011884:Radius / Q000000981:diagnostic imaging*; D013977:Tibia / Q000000981:diagnostic imaging*; D014057:Tomography, X-Ray Computed
chemical_list: D002136:Calcium, Dietary; D010281:Parathyroid Hormone; D015675:Osteocalcin; D002112:Calcifediol